The Israeli company will use the funds for the commercial launch of H.pylori drug TALICIA and two phase III clinical trials.
Omar Ishrak was a guest of honor at the International Conference for Innovations in Cardiovascular Systems.
Tikun Olam will be short of cannabis until its Kfar Yehoshua farms is approved.
Even if the bill passes until law, its implementation will still depend on Prime Minister Benjamin Netanyahu giving the green light.
Omar Ishrak heads a delegation of senior executives who will become acquainted with Medtronics recent acquisitions - Mazor Robotics, Nutrino and Visionsense.
Disinvestment by Teva from Israeli companies and thousands of employees laid off have had advantages for Israel's pharma industry, including successful startups.
"Globes" surveys Israel's medical cannabis sector, in which more than 100 companies are already operating.
Maurice Ferré says that the Israeli company's medical device technology is a game changer in incisionless surgery.
One year into the job, Teva CEO Kare Schultz has halted the plunge in the company's share price and restored investor confidence, but what of the future?
DLA Piper Canada partner Adv. Noam Goodman and iCan founder Saul Kaye speak to "Globes" about the cannabis opportunities Israel is missing.
CEO Aharon Lutzky talks about the $400 million medical cannabis company's special business model, and its ambitions.
The 8400 project aims to do for Israel's healthcare industry what the IDF's 8200 unit has done for cybersecurity.
Israeli medical companies are tackling the problem of obesity.
Medtronic is buying Prof. Moshe Shoham's Mazor for $1.6 billion, while he is looking forward to more robots and more startups.